On the Record · Labcorp
Labcorp acquisitions, on the record
The businesses Labcorp bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
several businesses and related assets acquired during 2023 (including Jefferson Health, Enzo BioChem, Providence Health and Services - Oregon, Tufts Medicine Legacy)Word for word“During the year ended December 31, 2023, the Company acquired several businesses and related assets for cash of approximately $ 671.5 .” 10-K for 2023 | acquisition | During the year ended December 31, 2023 | approximately $ 671.5 |
Fortrea Holdings Inc. (spin-off)Word for word“On June 30, 2023, the Company completed the previously announced spin-off of Fortrea from the Company.” 10-K for 2023 | divestiture | On June 30, 2023 | — |
the Company's interest in one joint ventureWord for word“The decrease in income for 2023 as compared with the corresponding period in 2022 was partially due to the sale of the Company's interest in one joint venture and the acquisition of the remaining interest in another joint venture during 2023.” 10-K for 2023 | divestiture | during 2023 | — |
the remaining interest in another joint ventureWord for word“The decrease in income for 2023 as compared with the corresponding period in 2022 was partially due to the sale of the Company's interest in one joint venture and the acquisition of the remaining interest in another joint venture during 2023.” 10-K for 2023 | acquisition | during 2023 | — |
a 15 % minority interest in SYNLABWord for word“On September 17, 2024, the Company announced that it entered into an agreement with Cinven, Inc. to acquire a 15 % minority interest in SYNLAB, a leader in medical diagnostic services and specialty testing in Europe, for approximately $ 155.9 (€ 140.0 ).” 10-K for 2024 | agreed acquisition | — | approximately $ 155.9 (€ 140.0 ) |
the clinical and outreach businesses of Baystate Medical CenterWord for word“During the year ended December 31, 2024, the Company acquired several businesses and related assets for cash of approximately $ 839.0 .” 10-K for 2024 | acquisition | During the year ended December 31, 2024 | — |
Beacon Laboratory Benefit Solutions, Inc.Word for word“During the year ended December 31, 2024, the Company sold the assets of its Beacon Laboratory Benefit Solutions, Inc. for $ 13.5 and recorded a gain of $ 6.4 .” 10-K for 2024 | divestiture | During the year ended December 31, 2024 | $ 13.5 |
SYNLAB (15% minority interest)Word for word“On September 17, 2024, the Company announced that it entered into an agreement with Cinven, Inc. to acquire a 15 % minority interest in SYNLAB, a leader in medical diagnostic services and specialty testing in Europe, for approximately $ 151.6 (€ 140.4 ).” 10-K for 2025 | acquisition | — | approximately $ 151.6 (€ 140.4 ) |
select clinical laboratory assets of Empire City Laboratories, Inc.Word for word“The purchase price for the transaction is up to $ 250.0 , including $ 165.0 paid at closing and up to $ 85.0 of additional consideration contingent on performance.” 10-K for 2025 | agreed acquisition | — | up to $ 250.0 |
select assets of the outreach laboratory services of Parkview Health System, Inc.Word for word“On November 13, 2025, the Company announced that it entered into an agreement with Parkview Health System, Inc. to acquire select assets of the health system’s outreach laboratory services for a purchase price of approximately $ 165.0 .” 10-K for 2025 | agreed acquisition | November 13, 2025 | approximately $ 165.0 |
| Fiscal year ended | Cash paid for acquisitions (net of cash acquired) | Cash received from selling businesses | Goodwill from acquisitions |
|---|---|---|---|
| 2016-12-31 | $548.6 million | $0 | $398.3 million |
| 2017-12-31 | $1.88 billion | $0 | $1.01 billion |
| 2018-12-31 | $117.8 million | $658.2 million | $70.5 million |
| 2019-12-31 | $876 million | $0 | $494.5 million |
| 2020-12-31 | $267.6 million | $3.1 million | $166.2 million |
| 2021-12-31 | $496.9 million | $0 | $298.4 million |
| 2022-12-31 | $1.16 billion | $1.6 million | $598.5 million |
| 2023-12-31 | $671.5 million | $0 | $296.9 million |
| 2024-12-31 | $839 million | $15.1 million | $390.5 million |
| 2025-12-31 | $582 million | $0 | $287.8 million |
Deal filings since 2016
- 2026-03-20 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2026-01-29 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2025-06-27 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2025-01-31 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2024-09-23 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2024-08-23 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2023-07-03 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2023-07-03 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2021-05-26 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-11-25 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-06-03 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-05-10 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2017-09-15 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-08-22 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-07-31 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-03-21 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
Read from Labcorp’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-24. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.